• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Novel post-AMI mortality risk model may perform better than existing references

byThomas SuandDeepti Shroff
June 8, 2020
in Cardiology
Reading Time: 3 mins read
PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Share on FacebookShare on Twitter

1. In this prospective modeling study of elderly adults who were hospitalized for acute myocardial infarction, the novel SILVER-AMI model appeared well-calibrated and had improved discrimination when compared the the commonly-used GRACE model.

2. Unique to the SILVER-AMI, several functional impairments were found to be independently associated with mortality and were included in the final multivariable model.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Acute myocardial infarction (AMI) risk guidelines are commonly used to assist clinical decision making, but existing models are based on a younger cohort with limited calibration in older adults, who are more vulnerable due to lower physiological reserve and greater numbers of comorbidities. This study proposed a novel stratified 6-month mortality risk model (SILVER-AMI) and tested its performance against that of the established Global Registry of Acute Coronary Events (GRACE) 6-month mortality risk score. While the two models shared many key variables such as heart rate and revascularization status, the incorporation of multiple additional risk factors such as functional impairment and comorbidity into the SILVER-AMI resulted in superior predictive accuracy when applied to the validation cohort. However, this new model was not externally validated, meaning that generated estimates ought to be used with caution in other populations. Another limitation was that the overall mortality rate in the internal dataset was lower than results from previous cohort studies would suggest. This trend may reflect either advances in care or bias due to a healthy enrollee effect. Finally, the cause of death was not distinguished in roughly a third of the sample population, making it difficult to link predictors with specific outcomes. Nonetheless, this model was relatively well calibrated and may be utilized to inform prognostication for older patients at time of discharge.

Click here to read the study in Annals of Internal Medicine

Click here to read an accompanying editorial in Annals of Internal Medicine

RELATED REPORTS

Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

Telemedicine may reduce interhospital transfers without increasing mortality

Relevant Reading: Risk Factors Associated With Major Cardiovascular Events 1 Year After Acute Myocardial Infarction

In-Depth [prospective cohort]: This multicenter observational study was conducted in the United States and involved 3006 patients over the age of 75 who were hospitalized for AMI and were subsequently discharged. The primary outcome was 6-month mortality as determined by medical records, death certificates, obituaries, or secondary report. Causes of death were classified as cardiovascular, non-cardiovascular, or unknown. A broad range of predictors were tested for inclusion in the final model, including general cognitive function, verbal fluency, upper-extremity strength, functional mobility, depressive symptoms, and fall history. Thresholds were established according to clinical relevance and distributions, and variables were then omitted based on missingness and prevalence (<5% or >95%). 15 variables were found to be associated with 6-month mortality, the strongest being receipt of in-hospital coronary artery bypass graft (protective), age, length of stay, self-reported health status, and unintentional weight loss. Consideration of functional impairments also significantly bolstered model performance. The final multivariable model demonstrated improved discrimination compared with the GRACE mortality risk score (AUC=0.84 vs. 0.76; P<0.001), and integrated predictiveness curves suggested that SILVER-AMI was able to better identify patients at both higher risk and lower risk.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseasemortality riskmyocardial infarctionrevascularizationSILVER-AMI
Previous Post

Treating acute migrane headaches with ubrogepant

Next Post

#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

RelatedReports

Behavioral dysregulation in infancy predicts later child mental health
Cardiology

Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring

September 12, 2026
Collage of medical tech icons circling a central chip with 'AI Roundup' title and 2 Minute Medicine logo in teal background.
AI Roundup

2MM: AI Roundup: NHS England expands Microsoft Copilot nationwide, ARPA-H advances autonomous cardiovascular AI, FDA advisors back Moderna’s mRNA influenza vaccine, and UpDoc earns first clearance for a patient-facing large language model

September 3, 2026
AAP recommends telemedicine to improve access to care
Imaging and Intervention

Telemedicine may reduce interhospital transfers without increasing mortality

July 6, 2026
Jessica Lau
Psychiatry

WHO launches 2026 global initiative to bridge the schizophrenia mortality gap

September 4, 2026
Next Post
#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

#VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

#VisualAbstract: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

#VisualAbstract: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Medical vaccine exemptions increase after elimination of nonmedical exemptions

4CMenB vaccine ineffective in reducing carriage prevalence of disease-causing meningococci

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
  • A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality
  • Ecopipam reduces relapse risk in pediatric Tourette syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.